Muscular Dystrophy News Home | Muscular Dystrophy News
WEBSep 13, 2024 · Teaching students about life with limb-girdle muscular dystrophy. As most of America’s children go back to school, I thought it’d be timely to offer readers my perspective, as a retired teacher and wheelchair user, on the beginning of an academic year. I began teaching middle school music and band in the fall of 1995. I was 22 years….
PTC Seeks FDA Approval for Translarna to Treat Nonsense …
WEBMar 7, 2017 · The U.S. Food and Drug Administration (FDA) acknowledged the filing over protest of PTC Therapeutics ’ new drug application (NDA) for Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The FDA granted Translarna standard review and assigned a target date of Oct. 24, 2017 for the agency to ...
Ullrich Congenital Muscular Dystrophy (UCMD)
WEBUllrich congenital muscular dystrophy (UCMD) is a rare hereditary muscle condition that manifests at birth or a few months after birth. It belongs to a group of disorders called collagen type 6-related myopathies and characterized by abnormalities in collagen type 6, a major protein that supports skeletal muscles.. Causes. UCMD is caused by a mutation in one of three genes that provide ...
Bethlem Myopathy - Muscular Dystrophy News
WEBBethlem myopathy, named after the Dutch doctor who first described it in 1976, is a rare and progressive form of muscular dystrophy.The condition mainly affects skeletal muscles and, to an extent, connective tissues. Less than 100 cases of Bethlem myopathy have been reported in the literature, making it a very rare form of muscular dystrophy.. Bethlem myopathy has not been associated with ...
Givinostat Continues to Delay DMD Progression in Long-term Study
WEBFeb 23, 2021 · The new data, from an ongoing seven-year study, was presented by Paolo Bettica, MD, PhD, chief medical officer at Italfarmaco, givinostat’s maker, at the virtual 28th International Conference on Duchenne and Becker Muscular Dystrophy, held online Feb. 20. “We are very encouraged to see that the long-term study with Givinostat continues to show a benefit in boys with DMD, which further ...
End Of An Era: MDA Telethon Ends Historic Run, Urgent Fight for...
WEBMay 6, 2015 · The Muscular Dystrophy Association (MDA) announced May 1 that after careful consideration and analysis of evolving realities pertaining to both television viewing habits and to philanthropic giving, it is time for the organization to discontinue producing and broadcasting the MDA telethon after 58 years on the air, and move beyond its historic Labor Day telethon — most recently named the ...
Dosing Begins in Phase 3 Trial of Pfizer’s Gene Therapy for Duchenne
WEBJan 14, 2021 · The U.S. Food and Drug Administration (FDA) recently awarded PF-06939926 fast track status based on positive results — such as sustained production of the mini-dystrophin protein in muscle tissues and motor function improvements — in an ongoing Phase 1b trial (NCT03362502) in boys and men with DMD.This designation helps to speed clinical development, regulatory review, and market entry ...
What Is Duchenne Muscular Dystrophy (DMD)?
WEBJan 19, 2022 · Duchenne muscular dystrophy is caused by mutations in the DMD gene, which provides cells with instructions for making a protein called dystrophin. Working in a complex with other proteins, dystrophin acts like a “shock absorber” in muscle cells, helping to protect the cells from wear-and-tear during the rigorous processes of muscle movements.
MD and Your Heart Monitor: 6 Things I Wish I'd Known
WEBJan 23, 2018 · 1. Use lotion to remove adhesive. Lotion is the easiest way to remove the adhesive on your skin left from the stickers that connect to the electrodes. It is also the least irritating for your skin, especially if you have sensitive skin like me. Let the lotion sink into your skin before wiping of the adhesive with some tissue paper.
UK Panel Expands Care Guidelines for Adults With DMD
WEBDec 14, 2021 · The guidelines were outlined in a report, “ Adult North Star Network (ANSN): Consensus Guideline For The Standard Of Care Of Adults With Duchenne Muscular Dystrophy,” published in the Journal of Neuromuscular Diseases. Due to treatment advancements in the past decade, including improved standard of care across treatment centers and access to clinical trials that have led to the approval of ...